Stem cell showdown: can early transplant beat standard care for scleroderma?
NCT ID NCT04464434
First seen Mar 29, 2026 · Last updated Jun 12, 2026 · Updated 15 times
Summary
This study tested whether giving a stem cell transplant early is better than standard immunosuppressive drugs for people with early, severe scleroderma (a rare autoimmune disease that causes skin hardening and organ damage). Sixty adults aged 18-65 were randomly assigned to either upfront stem cell transplant or usual care (cyclophosphamide followed by mycophenolate mofetil, with transplant as a backup). The goal was to see which strategy improves survival, lung function, and quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Amsterdam Rheumatology Centre
Amsterdam, Netherlands
-
Gaetano Pini-CTO
Milan, Italy
-
Ospedale San Raffaele
Milan, Italy
-
Radboudumc Nijmegen
Nijmegen, Netherlands
-
Sheffield Teaching Hospitals NHS Foundation Trust
Sheffield, United Kingdom
-
University Hospital Rome
Roma, Italy
-
University Medical Centre Leiden
Leiden, Netherlands
-
University Medical Centre Utrecht
Utrecht, Netherlands
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.